http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-105263522-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-082 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-20 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-42 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-08 |
| filingDate | 2014-05-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2019-03-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2019-03-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-105263522-B |
| titleOfInvention | The binding molecule of hepatitis B can be neutralized |
| abstract | The present invention relates to a kind of binding molecules, have hepatitis B neutralization activity and being incorporated into hepatitis B virus surface antigen (HBsAg) hypotype that at least one is selected from adw, adr, ayw and ayr.Binding molecule of the invention has excellent binding ability to HBsAg, so as to be incorporated into all four Main Subtypes of HBV, that is adw, adr, ayw and ayr, and neutralizing effect is shown to Main Subtype, and wide spectrum neutralizing effect is shown to a variety of HBsAg mutant antigens, therefore, the binding molecule is remarkably contributing to the prevention and treatment of hepatitis B. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-107001429-A |
| priorityDate | 2013-05-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 129.